deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 5-arm NCT01592370

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies

Sponsor: Bristol-Myers Squibb

Conditions Hodgkin Lymphoma Multiple Myeloma Non-Hodgkin's Lymphoma
Interventions Daratumumab Dexamethasone Ipilimumab Lirilumab Nivolumab Pomalidomide
Updated 36 times since 2017 Last updated: Oct 6, 2025 Started: Aug 2, 2012 Primary completion: Sep 25, 2020 Completion: Jul 9, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Hodgkin Lymphoma and Multiple Myeloma and is currently completed. Bristol-Myers Squibb leads this study, which shows 36 recorded versions since 2012 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Apr 2017 · 31 days · monthly snapshot~Apr 2017 – ~May 2017 · 30 days · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Oct 2017 · 4 months · monthly snapshot~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~May 2019 · 3 months · monthly snapshot~May 2019 – ~Aug 2019 · 3 months · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~May 2020 · 5 months · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Mar 2022 · 6 months · monthly snapshot~Mar 2022 – ~May 2022 · 2 months · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~May 2023 · 5 months · monthly snapshot~May 2023 – ~Sep 2023 · 4 months · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – present · 10 months · monthly snapshot

Change History

36 versions recorded

  1. Nov 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2025 — Nov 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

    Status: Active Not Recruiting → Completed

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. Oct 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 31 earlier versions

  1. Sep 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. May 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Dec 2022 — May 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Sep 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. May 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Mar 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Sep 2021 — Mar 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  8. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  9. Jun 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  10. May 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  11. Dec 2019 — May 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  12. Nov 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  13. Sep 2019 — Nov 2019 [monthly]

    Recruiting PHASE1_PHASE2

  14. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE1_PHASE2

  15. May 2019 — Aug 2019 [monthly]

    Recruiting PHASE1_PHASE2

  16. Feb 2019 — May 2019 [monthly]

    Recruiting PHASE1_PHASE2

  17. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE1_PHASE2

  18. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE1_PHASE2

  19. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE1_PHASE2

  20. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE1_PHASE2

  21. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE1_PHASE2

  22. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE1_PHASE2

  23. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE1_PHASE2

  24. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Active Not Recruiting → Recruiting · Phase: PHASE1 → PHASE1_PHASE2

  25. Oct 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  26. Jun 2017 — Oct 2017 [monthly]

    Recruiting PHASE1

  27. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE1

  28. Apr 2017 — May 2017 [monthly]

    Recruiting PHASE1

  29. Mar 2017 — Apr 2017 [monthly]

    Recruiting PHASE1

  30. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE1

  31. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Aug 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Janssen, LP
Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Athens, Greece , Aurora, United States , Baltimore, United States , Bologna, Italy , Boston, United States , Chorzów, Poland , Clovis, United States , Columbus, United States , Ghent, Belgium and 20 more locations